 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12» |
- | gentamicin sulfate / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: The Immunostimulatory Effects of Gentamicin (clinicaltrials.gov) - May 15, 2024
P2, N=33, Terminated, Sponsor: Singapore General Hospital
N=50 --> 33 | Trial completion date: Jan 2023 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Jan 2023 --> May 2024; slow recruitment due to COVID19
- |||||| SII-YFV / Serum Institute of India
Enrollment open: A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL (clinicaltrials.gov) - Nov 27, 2023
P3, N=1824, Recruiting, Sponsor: Serum Institute of India Pvt. Ltd.
N=50 --> 33 | Trial completion date: Jan 2023 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Jan 2023 --> May 2024; slow recruitment due to COVID19 Not yet recruiting --> Recruiting
- | Stamaril (yellow fever vaccine) / Sanofi, YF-VAX (yellow fever vaccine) / Sanofi
IND, Journal: Enhanced safety surveillance of STAMARIL (Pubmed Central) - Nov 27, 2023
This study supports the utility of STAMARIL in the EAP as an alternative solution for the YF vaccine shortage in the USA. SAEs were very rare and consistent with the known safety profile of STAMARIL.
- | Stamaril (yellow fever vaccine) / Sanofi
New trial: YF-INFECT: Yellow Fever Human Infection Model With YF-17D (clinicaltrials.gov) - Jun 13, 2023
P=N/A, N=30, Recruiting, Sponsor: Leiden University Medical Center
- | Stamaril (yellow fever vaccine) / Sanofi
Enrollment open, Trial completion date, Trial primary completion date: CYF-8: Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination (clinicaltrials.gov) - May 10, 2023
P4, N=80, Enrolling by invitation, Sponsor: University of Aarhus
SAEs were very rare and consistent with the known safety profile of STAMARIL. Active, not recruiting --> Enrolling by invitation | Trial completion date: Feb 2022 --> Feb 2024 | Trial primary completion date: Nov 2021 --> Feb 2024
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Stamaril (yellow fever vaccine) / Sanofi
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: CoGA: Coadministration of GA2 Sporozoites With Adjuvants (clinicaltrials.gov) - Feb 10, 2023
P1, N=45, Recruiting, Sponsor: Leiden University Medical Center
Active, not recruiting --> Enrolling by invitation | Trial completion date: Feb 2022 --> Feb 2024 | Trial primary completion date: Nov 2021 --> Feb 2024 Not yet recruiting --> Recruiting | N=25 --> 45 | Trial completion date: Nov 2023 --> Dec 2024 | Trial primary completion date: May 2023 --> Dec 2024
- || Stamaril (yellow fever vaccine) / Sanofi, YF-VAX (yellow fever vaccine) / Sanofi
Trial completion date: Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia (clinicaltrials.gov) - Jan 5, 2023
P2, N=690, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Not yet recruiting --> Recruiting | N=25 --> 45 | Trial completion date: Nov 2023 --> Dec 2024 | Trial primary completion date: May 2023 --> Dec 2024 Trial completion date: Apr 2027 --> Apr 2028
- | Stamaril (yellow fever vaccine) / Sanofi
Journal: Neurovirulence, viscerotropism and immunogenicity of live attenuated yellow fever 17D vaccine virus in non-human primates. (Pubmed Central) - Dec 24, 2022
WHO reference virus 168-73 and Stamaril™ as a control vaccine was used for comparison...The SII seed virus and vaccine complies to the WHO requirement for neurovirulence, viscerotropism and immunogenicity, when tested in comparison to WHO reference seed virus 168/73. All challenged animals showed 100 % seroconversion as early as day 14 and neutralizing antibody titers were sustainable at day 30 in all animals.
- || Stamaril (yellow fever vaccine) / Sanofi, SII-YFV / Serum Institute of India
P1 data, Journal: A phase I clinical study to assess safety and immunogenicity of yellow fever vaccine. (Pubmed Central) - Dec 20, 2022
The new YFV was found safe and immunogenic by IM as well as SC routes. The vaccine can be tested in further phases of clinical studies.
- | YF-VAX (yellow fever vaccine) / Sanofi
Journal: Absence of transmission of vYF next generation Yellow Fever vaccine in mosquitoes. (Pubmed Central) - Dec 16, 2022
Although comparison of vYF-247 to reference vaccines could not be completed to yield significant results, we showed that vYF-247 was not transmitted by both Aedes species, either laboratory strains or field-collected populations, compared to clinical strain S-79 at the highest inoculation dose. Combined with the undetectable to low level viremia detected in vaccinees, transmission of the vYF-247 vaccine by mosquitoes is highly unlikely.
- | Stamaril (yellow fever vaccine) / Sanofi
Journal: Bis(Benzofuran-1,3-N,N-heterocycle)s as Symmetric and Synthetic Drug Leads against Yellow Fever Virus. (Pubmed Central) - Oct 28, 2022
These conjugates exhibited the most compelling efficacy and selectivity with an EC of <3.54 μM and SI of >15.3. The results are valuable for the development of novel antiviral drug leads against emerging diseases.
- YF-VAX (yellow fever vaccine) / Sanofi
Low replication and absence of transmission of vYF next generation Yellow Fever Vaccine candidate in mosquitoes (Convention Center - Hall 4A (4th Floor); In-Person-Only) - Oct 9, 2022 - Abstract #ASTMH2022ASTMH_1846;
These results were confirmed with field-collected mosquitoes from Asia, Latin America and Africa.Even if in some limited cases the vYF vaccine candidate could infect and to a very minor extent disseminate in mosquitoes, no transmission potential was detected. Together with the undetectable to low level viremia observed after vaccination of human volunteers, these data demonstrate that the dissemination of the vYF vaccine by mosquitoes is highly unlikely.
- YF-VAX (yellow fever vaccine) / Sanofi
Evaluation of safety and immuno-efficacy of the next generation live attenuated yellow fever vaccine in cynomolgus macaques (Convention Center - Hall 4A (4th Floor); In-Person-Only) - Oct 9, 2022 - Abstract #ASTMH2022ASTMH_928;
Finally, vYF provided effective resistance to virulent challenge with wild-type YFV Asibi including complete protection against YFV-induced mortality, pathology, dysregulation of blood and liver soluble biomarkers and a significant reduction in viremia and viral load to the limit of detection. These data suggest that vYF is safe and would provide protection against YFV infection in clinical practice, at least similar to that achieved with currently marketed YF-17D vaccines.
- | Imojev (live attenuated Japanese encephalitis chimeric virus vaccine) / Sanofi, Stamaril (yellow fever vaccine) / Sanofi, Ixiaro (IC51) / Valneva
New P2 trial: An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity (clinicaltrials.gov) - Oct 6, 2022
P2, N=70, Not yet recruiting, Sponsor: Singapore General Hospital
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Stamaril (yellow fever vaccine) / Sanofi
New P1 trial: CoGA: Coadministration of GA2 Sporozoites With Adjuvants (clinicaltrials.gov) - Jul 21, 2022
P1, N=25, Not yet recruiting, Sponsor: Leiden University Medical Center
- | Stamaril (yellow fever vaccine) / Sanofi
New trial: Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination (clinicaltrials.gov) - Jul 11, 2022
P=N/A, N=60, Not yet recruiting, Sponsor: ANRS, Emerging Infectious Diseases
- |||||||||| SII-YFV / Serum Institute of India
New P3 trial: A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants (clinicaltrials.gov) - Jul 7, 2022
P3, N=2216, Not yet recruiting, Sponsor: Serum Institute of India Pvt. Ltd.
- |||||||||| SII-YFV / Serum Institute of India
New P3 trial: A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL (clinicaltrials.gov) - Jun 15, 2022
P3, N=2280, Not yet recruiting, Sponsor: Serum Institute of India Pvt. Ltd.
- | gentamicin sulfate / Generic mfg.
Enrollment open: The Immunostimulatory Effects of Gentamicin (clinicaltrials.gov) - May 17, 2022
P2, N=50, Recruiting, Sponsor: Singapore General Hospital
These data suggest that vYF is safe and would provide protection against YFV infection in clinical practice, at least similar to that achieved with currently marketed YF-17D vaccines. Not yet recruiting --> Recruiting
- Stamaril (yellow fever vaccine) / Sanofi
Developing a novel HIV cure strategy: retargeting potent cytotoxic T cells to kill HIV-infected cells () - May 12, 2022 - Abstract #AIDS2022AIDS_2536;
We have developed a novel immunotherapy concept in which epitope-specific CTLs induced by vaccination can be redirected towards HIV-infected cells. This novel technology is highly specific and easily adaptable to recognize any target of interest while obviating the need for ex vivo modification and expansion, thus holding great potential for various diseases.
- ||| Stamaril (yellow fever vaccine) / Sanofi, YF-VAX (yellow fever vaccine) / Sanofi
Enrollment closed: Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia (clinicaltrials.gov) - Apr 29, 2022
P2, N=690, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
This novel technology is highly specific and easily adaptable to recognize any target of interest while obviating the need for ex vivo modification and expansion, thus holding great potential for various diseases. Recruiting --> Active, not recruiting
- | gentamicin sulfate / Generic mfg.
New P2 trial: The Immunostimulatory Effects of Gentamicin (clinicaltrials.gov) - Mar 31, 2022
P2, N=50, Not yet recruiting, Sponsor: Singapore General Hospital
- | Stamaril (yellow fever vaccine) / Sanofi
Trial completion, Trial completion date, Head-to-Head: Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) (clinicaltrials.gov) - Feb 1, 2022
P4, N=1630, Completed, Sponsor: Epicentre
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: May 2021 --> Dec 2021
- |||| Stamaril (yellow fever vaccine) / Sanofi, YF-VAX (yellow fever vaccine) / Sanofi
Enrollment open: Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia (clinicaltrials.gov) - Oct 4, 2021
P2, N=690, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed | Trial completion date: May 2021 --> Dec 2021 Not yet recruiting --> Recruiting
- ||||| Stamaril (yellow fever vaccine) / Sanofi, YF-VAX (yellow fever vaccine) / Sanofi
New P2 trial: Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia (clinicaltrials.gov) - Aug 18, 2021
P2, N=690, Not yet recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- ||||| Stamaril (yellow fever vaccine) / Sanofi, YF-VAX (yellow fever vaccine) / Sanofi
New P2 trial: Study on an Investigational Yellow Fever Vaccine Compared with Stamaril in Adults in Europe and Asia (EUDRACT) - Jun 10, 2021
P2, N=690, Ongoing, Sponsor: Sanofi Pasteur
- | Stamaril (yellow fever vaccine) / Sanofi
Enrollment closed, Trial completion date: CYF-8: Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination (clinicaltrials.gov) - Mar 24, 2021
P4, N=80, Active, not recruiting, Sponsor: University of Aarhus
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Sep 2021 --> Feb 2022
- | Stamaril (yellow fever vaccine) / Sanofi
Enrollment closed, Trial completion date, Head-to-Head: Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) (clinicaltrials.gov) - Dec 17, 2020
P4, N=1630, Active, not recruiting, Sponsor: Epicentre
Recruiting --> Active, not recruiting | Trial completion date: Sep 2021 --> Feb 2022 Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> May 2021
- ||||||| Mosquirix (RTS,S) / GSK
Trial completion: Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. (clinicaltrials.gov) - Nov 17, 2020
P3, N=699, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> May 2021 Active, not recruiting --> Completed
- | Stamaril (yellow fever vaccine) / Sanofi
Trial completion date, Trial primary completion date: CYF-8: Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination (clinicaltrials.gov) - Nov 4, 2020
P4, N=80, Recruiting, Sponsor: University of Aarhus
Active, not recruiting --> Completed Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021
- | Stamaril (yellow fever vaccine) / Sanofi
Trial completion, Enrollment change: Yellow Fever Vaccine on Statin/ Non Statin Subjects (clinicaltrials.gov) - Mar 23, 2020
P2, N=37, Completed, Sponsor: Singapore General Hospital
Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021 Recruiting --> Completed | N=70 --> 37
- | Stamaril (yellow fever vaccine) / Sanofi
Enrollment open: CYF-8: Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination (clinicaltrials.gov) - Sep 12, 2019
P4, N=80, Recruiting, Sponsor: University of Aarhus
Recruiting --> Completed | N=70 --> 37 Not yet recruiting --> Recruiting
- | Stamaril (yellow fever vaccine) / Sanofi
New P4 trial: CYF-8: Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination (clinicaltrials.gov) - Sep 9, 2019
P4, N=80, Not yet recruiting, Sponsor: University of Aarhus
- | Stamaril (yellow fever vaccine) / Sanofi
Enrollment open, Head-to-Head: Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) (clinicaltrials.gov) - Feb 21, 2019
P4, N=1630, Recruiting, Sponsor: Epicentre
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | Stamaril (yellow fever vaccine) / Sanofi
Trial completion, Trial completion date, Trial primary completion date: The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. (clinicaltrials.gov) - Jan 18, 2019
P3, N=71, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Dec 2017 | Trial primary completion date: Nov 2017 --> Feb 2017
- | Stamaril (yellow fever vaccine) / Sanofi
Enrollment change, Trial completion date, Head-to-Head: Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) (clinicaltrials.gov) - Nov 28, 2018
P4, N=1630, Active, not recruiting, Sponsor: Epicentre
Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Dec 2017 | Trial primary completion date: Nov 2017 --> Feb 2017 N=960 --> 1630 | Trial completion date: Dec 2019 --> Dec 2020
- | Stamaril (yellow fever vaccine) / Sanofi
Trial completion: Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea (clinicaltrials.gov) - Jul 17, 2018
P=N/A, N=622, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
N=960 --> 1630 | Trial completion date: Dec 2019 --> Dec 2020 Recruiting --> Completed
- ||| Stamaril (yellow fever vaccine) / Sanofi
New trial: Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea (clinicaltrials.gov) - Jul 16, 2018
P=N/A, N=600, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- | Stamaril (yellow fever vaccine) / Sanofi
Trial primary completion date: The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. (clinicaltrials.gov) - Mar 3, 2018
P3, N=71, Active, not recruiting, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Recruiting --> Completed Trial primary completion date: Oct 2017 --> Nov 2017
- ||| Mosquirix (RTS,S) / GSK
Trial completion date: Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. (clinicaltrials.gov) - Mar 3, 2018
P3, N=699, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Oct 2017 --> Nov 2017 Trial completion date: Sep 2020 --> Dec 2020
- | Stamaril (yellow fever vaccine) / Sanofi
Enrollment closed, Head-to-Head: Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) (clinicaltrials.gov) - Feb 28, 2018
P4, N=960, Active, not recruiting, Sponsor: Epicentre
Trial completion date: Sep 2020 --> Dec 2020 Recruiting --> Active, not recruiting
- | Stamaril (yellow fever vaccine) / Sanofi
Enrollment open, Head-to-Head: Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) (clinicaltrials.gov) - Nov 8, 2017
P4, N=960, Recruiting, Sponsor: Epicentre
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Mosquirix (RTS,S) / GSK
Enrollment closed: Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. (clinicaltrials.gov) - Oct 12, 2017
P3, N=699, Active, not recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Stamaril (yellow fever vaccine) / Sanofi
Trial primary completion date, Head-to-Head: Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) (clinicaltrials.gov) - Sep 5, 2017
P4, N=960, Not yet recruiting, Sponsor: Epicentre
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2017 --> Mar 2018
- | Stamaril (yellow fever vaccine) / Sanofi
Trial primary completion date: The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. (clinicaltrials.gov) - Jul 28, 2017
P3, N=71, Active, not recruiting, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Trial primary completion date: Dec 2017 --> Mar 2018 Trial primary completion date: May 2017 --> Oct 2017
- |||||| Mosquirix (RTS,S) / GSK
Enrollment open: Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. (clinicaltrials.gov) - Jun 7, 2017
P3, N=700, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: May 2017 --> Oct 2017 Not yet recruiting --> Recruiting
- || Mosquirix (RTS,S) / GSK
Trial primary completion date: Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen (clinicaltrials.gov) - Apr 25, 2017
P2, N=511, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2009 --> Sep 2008
- ||||| Mosquirix (RTS,S) / GSK
Trial initiation date, Trial primary completion date: Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. (clinicaltrials.gov) - Apr 18, 2017
P3, N=700, Not yet recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Oct 2009 --> Sep 2008 Initiation date: Jan 2017 --> Apr 2017 | Trial primary completion date: Aug 2017 --> Apr 2018
- | Stamaril (yellow fever vaccine) / Sanofi
New P4 trial, Head-to-Head: Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) (clinicaltrials.gov) - Dec 13, 2016
P4, N=960, Not yet recruiting, Sponsor: Epicentre
- ||||| Mosquirix (RTS,S) / GSK
Trial initiation date: Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. (clinicaltrials.gov) - Dec 2, 2016
P3, N=700, Not yet recruiting, Sponsor: GlaxoSmithKline
Initiation date: Jan 2017 --> Apr 2017 | Trial primary completion date: Aug 2017 --> Apr 2018 Initiation date: Jun 2016 --> Jan 2017